Lenalidomide Mylan (Lenalidomide)

Lenalidomide is used in hematologic malignancies and related disorders, targeting abnormal plasma cells and myeloid clones.

• Multiple Myeloma: improves progression‑free survival and overall response rates in patients who have received prior therapy.
• Myelodysplastic Syndromes (del(5q)): reduces transfusion dependence and can lead to cytogenetic remission in eligible adults.
• Mantle Cell Lymphoma: used in combination regimens to achieve disease control in relapsed or refractory cases.

• Lenalidomide binds to the cereblon component of the CRL4 E3 ubiquitin ligase complex, altering substrate specificity. This leads to degradation of transcription factors Ikaros and Aiolos, resulting in anti‑angiogenic, immunomodulatory, and direct anti‑tumor effects that inhibit proliferation of malignant plasma cells and myeloid clones.

Lenalidomide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Fatigue: persistent tiredness affecting daily activities.
• Diarrhea: loose stools that may require fluid replacement.
• Nausea: upset stomach often occurring after dosing.
• Rash: mild skin eruptions or itching.
• Constipation: difficulty passing stool.
• Peripheral edema: swelling of extremities.

Serious or Rare Side Effects

• Thromboembolic events: deep vein thrombosis or pulmonary embolism.
• Severe neutropenia: marked reduction in neutrophil count increasing infection risk.
• Severe thrombocytopenia: low platelet counts leading to bleeding.
• Secondary primary malignancies: emergence of new cancers.
• Hepatotoxicity: elevated liver enzymes or liver injury.

Before initiating Lenalidomide, several safety considerations should be reviewed.

• Pregnancy risk: contraindicated in pregnancy (Category X); ensure effective contraception.
• Thromboembolic prophylaxis: assess need for anticoagulation in high‑risk patients.
• Renal function: adjust monitoring in patients with impaired kidney function.
• Hematologic monitoring: perform regular CBC to detect neutropenia or thrombocytopenia.
• Infection risk: monitor for signs of infection and manage promptly.
• Store at ambient temperature: keep tablets below 25°C in the original container, protect from moisture and light.

Lenalidomide can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin): may reduce plasma concentrations of lenalidomide.
• Anticoagulants (e.g., warfarin): increased risk of bleeding when combined with lenalidomide.

Moderate Interactions (Monitor Closely)

• P-glycoprotein inhibitors (e.g., verapamil): may increase lenalidomide exposure.
• Immunosuppressants (e.g., cyclosporine): may enhance immunomodulatory effects.
• Vaccines (live attenuated): reduced efficacy; avoid concurrent administration.